On July 29, GIANT BIOGENE rose 5.54% in regular trading, trading at HK$30.54/share, with turnover of approximately HK$71.74 million.
On the news front, HK-listed new consumption concept stocks rallied collectively during the session, with sector linkage effects clearly visible. At the company level, GIANT BIOGENE's medical aesthetics product matrix has continued to expand: its 753 Collagen Needle was officially launched in June as China's first recombinant Type I collagen facial injectable, differentiating itself in the Type III collagen-dominated injection market. In the same month, the company's self-developed crosslinked recombinant Type III full-length sequence collagen filler received NMPA approval, becoming the world's first such product indicated for neck wrinkle improvement.
Multiple brokerages maintain positive ratings on the stock. One institution maintains an Outperform rating with a target price of HK$40, noting differentiated advantages of the newly approved products. Another maintains a Buy rating with a HK$45 target, expecting the company to return to a growth trajectory with new product launches and medical aesthetics commercialization driving momentum.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments